Vir Biotechnology (VIR) Profit After Tax (2018 - 2026)
Vir Biotechnology's (VIR) quarterly Profit After Tax came in at -$125.7 million in Q1 2026, down 3.91% year-on-year from -$130.8 million in Q1 2025, and down 192.84% quarter-over-quarter from -$42.9 million in Q4 2025.
Vir Biotechnology (VIR) Profit After Tax (2018 - 2026) Analysis & Trends
Vir Biotechnology has disclosed Profit After Tax across 9 years of filings, most recently posting -$125.7 million for Q1 2026.
- Profit After Tax for Q1 2026 came in at -$125.7 million, down 3.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$442.7 million (up 23.36% YoY), and the FY2025 annual result was -$438.0 million, up 16.09% from the prior year.
- Profit After Tax came in at -$125.7 million for Q1 2026 at Vir Biotechnology, down from -$42.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $518.6 million in Q1 2022 to a low of -$213.7 million in Q3 2024.
- The 5-year median for Profit After Tax is -$116.0 million (2023), against an average of -$69.7 million.
- Peak annual rise in Profit After Tax reached 407.04% in 2022, while the deepest fall reached 223.75% in 2022.
- Vir Biotechnology's Profit After Tax stood at -$101.6 million in 2022, then decreased by 14.14% to -$116.0 million in 2023, then advanced by 9.82% to -$104.6 million in 2024, then soared by 58.96% to -$42.9 million in 2025, then tumbled by 192.84% to -$125.7 million in 2026.
- The last three Profit After Tax figures came in at -$125.7 million (Q1 2026), -$42.9 million (Q4 2025), and -$163.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Vir Biotechnology | 1.35 Bn | 1.35 Bn | - | -125.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.70 Mn |
| Dec 31, 2025 | -42.92 Mn |
| Sep 30, 2025 | -163.14 Mn |
| Jun 30, 2025 | -110.96 Mn |
| Mar 31, 2025 | -120.97 Mn |
| Dec 31, 2024 | -104.59 Mn |
| Sep 30, 2024 | -213.72 Mn |
| Jun 30, 2024 | -138.38 Mn |
| Mar 31, 2024 | -65.28 Mn |
| Dec 31, 2023 | -115.97 Mn |
| Sep 30, 2023 | -163.41 Mn |
| Jun 30, 2023 | -194.78 Mn |
| Mar 31, 2023 | -140.96 Mn |
| Dec 31, 2022 | -101.60 Mn |
| Sep 30, 2022 | 175.31 Mn |
| Jun 30, 2022 | -76.49 Mn |
| Mar 31, 2022 | 518.62 Mn |
| Dec 31, 2021 | 525.25 Mn |
| Sep 30, 2021 | 110.43 Mn |
| Jun 30, 2021 | 61.81 Mn |